Nanosystem formulations for rectal microbicides: A call for more research

Therapeutic Delivery

Volumn 3, Issue 1, 2012, Pages 1-3

  Sarmento, Bruno ^a,b   Das Neves, José ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

Author keywords

antiretroviral drugs; HIV AIDS; nanomedicine; nanotechnology; prevention; rectal drug delivery; sexually transmitted diseases; VivaGel

Indexed keywords

ANTIRETROVIRUS AGENT; DAPIVIRINE; DENDRIMER; MICROBICIDE; NANOPARTICLE; POLYCAPROLACTONE; TECHNETIUM SULFUR COLLOID TC 99M; TENOFOVIR; VIVAGEL;

COLON MUCOSA; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RESEARCH; DRUG SAFETY; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NANOSYSTEM; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; RECTUM MUCOSA; REVIEW; VIRUS TRANSMISSION;

EID: 84055217599     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.139     Document Type: Review

References (23)

1. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. Geneva, Switzerland (2010).
2. Ariën KK, Jespers V, Vanham G. HIV sexual transmission and microbicides. Rev. Med. Virol. 21, 110-133 (2011).
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010).
4. McGowan I. Rectal microbicides: a new focus for HIV prevention. Sex. Transm. Infect. 84, 413-417 (2008).
5. McGowan I. Rectal microbicides: can we make them and will people use them? AIDS Behav. 15(Suppl. 1), S66-S71 (2011).
6. Boily MC, Baggaley RF, Wang L et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect. Dis. 9, 118-129 (2009).
7. Jin F, Jansson J, Law M et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS 24, 907-913 (2010).
8. das Neves J, Amiji MM, Bahia MF, Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/ AIDS. Adv. Drug Deliv. Rev. 62, 458-477 (2010).
9. Mallipeddi R, Rohan LC. Nanoparticle-based vaginal drug delivery systems for HIV prevention. Expert Opin. Drug Deliv. 7, 37-48 (2010).
10. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat. Rev. Immunol. 8, 447-457 (2008). (Pubitemid 351735878)
11. Javanbakht M, Murphy R, Gorbach P, LeBlanc MA, Pickett J. Preference and practices relating to lubricant use during anal intercourse: implications for rectal microbicides. Sex. Health 7, 193-198 (2010).
12. Sudol KM, Phillips DM. Relative safety of sexual lubricants for rectal intercourse. Sex. Transm. Dis. 31, 346-349 (2004). (Pubitemid 38691963)
13. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 29, 1035-1041 (1988).
14. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61, 158-171 (2009).
15. Carballo-Dieguez A, Exner T, Dolezal C, Pickard R, Lin P, Mayer KH. Rectal microbicide acceptability: results of a volume escalation trial. Sex. Transm. Dis. 34, 224-229 (2007). (Pubitemid 46606747)
16. Hendrix CW, Fuchs EJ, Macura KJ et al. Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates. Clin. Pharmacol. Ther. 83, 97-105 (2008).
17. Louissaint NA, Nimmagadda S, Fuchs EJ et al. Distribution of cell-free and cell-associated HIV surrogates in the colon following simulated receptive anal intercourse in men who have sex with men. J. Acquir. Immune Defic. Syndr. doi:10.1097/ QAI.1090b1013e3182373b3182375e (2011) (Epub ahead of print).
18. das Neves J, Amiji M, Sarmento B. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe? Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3, 389-399 (2011).
19. Tyssen D, Henderson SA, Johnson A et al. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One 5, e12309 (2010).
20. Dezzutti CS, James VN, Ramos A et al. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob. Agents Chemother. 48, 3834-3844 (2004). (Pubitemid 39304612)
21. Abner SR, Guenthner PC, Guarner J et al. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J. Infect. Dis. 192, 1545-1556 (2005). (Pubitemid 41504690)
22. Patton DL, Cosgrove Sweeney YT, McCarthy TD, Hillier SL. Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob. Agents Chemother. 50, 1696-1700 (2006).
23. das Neves J, Michiels J, Ariën KK et al. Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm. Res. doi:10.1007/s11095-011- 0622-3 (2011) (Epub ahead of print).